Afya (NASDAQ:AFYA – Get Free Report) is anticipated to release its Q2 2026 results before the market opens on Wednesday, August 12th. Analysts expect the company to announce earnings of $0.4054 per share and revenue of $190.5110 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 13, 2026 at 5:00 PM ET.
Afya Stock Down 1.8%
Afya stock opened at $13.94 on Wednesday. The company has a current ratio of 1.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.42. The firm’s fifty day moving average price is $14.35 and its two-hundred day moving average price is $14.44. The firm has a market capitalization of $1.31 billion, a price-to-earnings ratio of 9.11, a price-to-earnings-growth ratio of 1.41 and a beta of 0.34. Afya has a 1-year low of $13.00 and a 1-year high of $16.50.
Wall Street Analysts Forecast Growth
Several research firms recently weighed in on AFYA. Bank of America restated a “neutral” rating on shares of Afya in a report on Thursday, June 11th. JPMorgan Chase & Co. cut their target price on Afya from $21.50 to $21.00 and set a “neutral” rating on the stock in a research note on Monday, June 22nd. Wall Street Zen lowered Afya from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 2nd. Weiss Ratings downgraded Afya from a “hold (c)” rating to a “hold (c-)” rating in a research report on Friday. Finally, Zacks Research lowered Afya from a “strong-buy” rating to a “hold” rating in a report on Wednesday, May 6th. One investment analyst has rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $17.88.
Insider Transactions at Afya
In other Afya news, VP Gomiero Mirella Basolli sold 10,000 shares of the business’s stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $14.80, for a total value of $148,000.00. Following the transaction, the vice president directly owned 34,530 shares in the company, valued at $511,044. The trade was a 22.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Lelio De Souza Junior sold 36,204 shares of the stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $15.00, for a total transaction of $543,060.00. The SEC filing for this sale provides additional information. Insiders have sold 87,745 shares of company stock valued at $1,314,175 in the last 90 days.
Institutional Investors Weigh In On Afya
Hedge funds have recently modified their holdings of the stock. Daiwa Securities Group Inc. purchased a new position in Afya in the fourth quarter valued at approximately $43,000. Militia Capital Partners LP bought a new stake in shares of Afya in the second quarter valued at $71,000. Quantbot Technologies LP bought a new stake in shares of Afya in the second quarter valued at $117,000. Van ECK Associates Corp lifted its position in shares of Afya by 15.7% during the 3rd quarter. Van ECK Associates Corp now owns 10,170 shares of the company’s stock valued at $159,000 after buying an additional 1,377 shares during the last quarter. Finally, State of Wyoming bought a new stake in Afya in the 2nd quarter valued at about $164,000. Institutional investors own 88.02% of the company’s stock.
About Afya
Afya Ltd. operates as a leading provider of medical education and training services in Brazil. The company offers a comprehensive suite of educational programs that span undergraduate medical degrees, residency exam preparation, continuing medical education (CME) and digital learning platforms. Through a network of partner institutions and its own campus operations, Afya supports students at every stage of the medical training continuum, from enrollment in medical schools to ongoing professional development for practicing physicians.
At the core of Afya’s offerings is its undergraduate medical program, delivered through a combination of in-person courses at affiliated campuses and fully digital curricula.
Featured Articles
- Five stocks we like better than Afya
- Palantir Soars 30% After Blockbuster Earnings—Is the Rally Just Getting Started?
- Visa’s BioCatch Deal Could Make Fraud Prevention a Bigger Business
- Caterpillar’s Record Quarter May Have Reset the Stock’s Ceiling
- The Real Reason Amazon Hit a $3 Trillion Valuation
Receive News & Ratings for Afya Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Afya and related companies with MarketBeat.com's FREE daily email newsletter.
